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The gut microbiota are known to have a profound influence on both mucosal and
systemic immunity and are important for gastrointestinal (GI) function. In addition,
new evidence shows that the microbiota significantly influence neurodevelopment and
behavior. Immune dysfunction and GI distress are extremely common in individuals with
autism spectrum disorders (ASD). A growing body of evidence suggests that individuals
with ASD have significant aberrations in the composition of their gut microbiota, known
as dysbiosis. However, these studies have focused on the bacterial components of
the microbiota, leaving the fungal microbiota in ASD poorly studied. Increases in fungal
species such asCandida albicans are associated with inflammatory bowel disorders, and
have recently been implicated in several neurological disorders including schizophrenia.
We aimed to determine if children with ASD exhibit elevations in antibodies that target C.
albicans, indicating current or previous overgrowth of this fungal species. We measured
anti-C. albicans immunoglobulin (IgG) in plasma from 80 children enrolled in the UC Davis
MIND Institute CHARGE study. Measurements were acquired using a commercial ELISA
kit. Plasma anti-C. albicans antibody positivity was found in 36.5% (19/52) of children
with ASD. Anti-C. albicans antibodies in typically developing controls was (14.3%; 4/28).
Overall, ASD children had a higher rate of high-positive values compared to typically
developed children with an unadjusted odds ratio of 3.45 (95% confidence interval,
1.0409 to 11.4650; p = 0.041, two-tailed). GI dysfunction was found in about half of
the ASD children who were positive for anti-Candida IgG. This study provides evidence
of a new microbial risk factor for ASD.
Keywords: autism, Candida, antibodies, immunity, behavior
INTRODUCTION
Autism spectrum disorders (ASD) are a group of heterogeneous neurodevelopmental disorders
defined by deficiencies in social interactions, cognition and communication, and stereotypical and
repetitive behaviors (1). Although specific genetic mutations account for 10–20% of causes for ASD,
heritability risks are high and could include genes that lead to susceptibility for environmental
exposures, or similar epigenetic mechanisms brought about by shared household exposures to
environment (2). Environmental risk factors for having a child with ASD include gestational
exposure to pollution and pesticides, and maternal infections and inflammation during pregnancy
(3–5). ASD is also linked to familial autoimmunity and asthma (6–8) and many individuals
with ASD have significant immune dysfunction (9, 10). Gastrointestinal (GI) dysfunction is also
common in these individuals, with at least 50% of individuals with ASD experiencing GI issues (11).
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Gastrointestinal and immune dysfunction has been linked
to aberrant composition of the microbiota, known as dysbiosis
(12). Recently, researchers have identified significant bacterial
dysbiosis in individuals with ASD (13–23). Bacterial dysbiosis
can be caused by a variety of insults including frequent antibiotic
use, which can also increase the risk of fungal overgrowth in
the GI tract. Candida albicans is generally considered a passive
commensal yeast of the GI and genitourinary tracts, however,
it has polymorphic capabilities and under certain conditions,
including altered competition within the gut, it is capable of
transitioning to its pathogenic and invasive fungal form (24).
The presence of Candida species during recolonization after
antibiotics also contribute to dysbiosis (25) and are associated
with GI disorders such as celiac disease and inflammatory bowel
disorders (26–28). These competitive relationships of bacterial
versus fungal microbiota are complex and still being investigated,
as newer techniques develop to identify them (24).
Overgrowth of Candida species has been noted in ASD in
a few studies utilizing culture-based techniques (29–31) and
more recently in a study using sequencing techniques, which
found Candida to be present in the stool of ASD children in
nearly twice the numbers of typically developed children (21).
Elevations of d-arabinitol, a suspected metabolic byproduct of
Candida species, was found in a study of 21 Italian children
with ASD (32). D-arabinitol was also significantly reduced in
ASD children after probiotic administration, and this correlated
with improved behaviors including ability to concentrate (33).
Fungal infections are an emerging area of research interest
in ASD, and exposure can also be identified by looking at
immunoglobulin (Ig) that target fungal antigens. They may
be present in individuals with dysbiosis, as this may lead to
breeches in intestinal barrier function and subsequent immune
responses to commensal microbiota, including the production of
IgG antibodies indicating current or previous overgrowth of this
fungal species (34, 35). In schizophrenia, significantly elevated
IgG antibodies to fungal microbiota have been seen, especially in
males, however, they were also seen in bipolar females associated
with lower cognitive scores (36). So far these antibodies have
not been studied in individuals with ASD, therefore we aimed
to determine if similar antibodies are over-represented in ASD
children with and without GI dysfunction compared to their
typically developing (TD) counterparts.
METHODS
Study Participants
Eighty participants ranging in age from 3 to 13 years old were
enrolled in this study as part of the larger population based
cohort Childhood Autism Risk from Genetics and Environment
(CHARGE) study (37). ASD diagnoses were confirmed using
the Autism Diagnostic Interview-Revised (ADI-R), and the
Autism Diagnostic Observation Schedule (ADOS) at the time
of enrollment. Social Communication Questionnaire (SCQ)
was used to screen for characteristics of ASD in the typically
developed children. Criteria for enrollment in the typically
developed groups were scores of below 15 on the SCQ and
above 70 on the Mullen Scales of Early Learning (MSEL) and
Vineland Adaptive Behavior Score (VABS). There were n =
52 ASD subjects (median age 7.42 years (IQR: 5.17–9.42); 8
females) and n = 28 TD (median age 6.5 years (IQR: 5.58–
8.33); 3 females). All subjects were administered the Aberrant
Behavior Checklist (ABC) assessment. Parents also completed
a CHARGE GI history (GIH) survey and GI symptom survey,
based upon Rome III Diagnostic Questionnaire for the Pediatric
Functional GI Disorders (22, 38) to identify symptoms of GI
dysfunction including abdominal pain, gas/bloating, diarrhea,
constipation, pain on stooling, vomiting, sensitivity to foods,
difficulty swallowing, and blood in stool or vomit. Participants
were excluded if they had inflammatory bowel disease (IBD)
or other GI pathology, recent evidence of a GI infection
and/or were taking medication that might alter GI function
such as stool softeners which can alter motility or recent
antibiotics/antifungals that can induce dysbiosis. In addition,
participants with seizure disorder, genetic disorders, or other
chronic diseases and/or infections were also excluded.
This study was approved by institutional review boards for the
State of California and the University of California, Davis. Both
written and informed consent was obtained from a legal guardian
for all study participants prior to data collection in accordance
with the UC Davis IRB protocol.
Blood Collection and Enzyme-Linked
Immunosorbent Assay
Peripheral blood was collected from each subject in acid-
citrate dextrose Vacutainers (BD Biosciences; San Jose, Ca).
Blood was centrifuged and plasma harvested and stored at
−80◦C until time of assay. Human anti-Candida albicans
IgG was measured using enzyme-linked immunosorbent assay
with a commercially available kit (Abcam, Cambridge, MA,
USA) following the manufacturer’s instructions. According to
manufacturer’s recommendations, 96 well plates were pre-coated
with Candida capture antigens. Plasma samples were diluted
1:100 with diluent provide, and 100 µL of diluted plasma,
positive, negative, and cut-off controls were added to the plate
in duplicate, leaving two blank wells per plate, and incubated
in the dark for 1 h at 37◦C. Wells were aspirated and washed
three times with provided washing solution. 100 µL Candida
albicans anti-IgG HRP Conjugate was added to all wells except
for blank wells, and incubated for 30min in the dark at room
temperature, then washed again three times. One hundred
microliter 3,3’,5,5’-tetramethylbenzidine (TMB) solution was
added to the wells and incubated for 15min, the reaction was
stopped with reagent provided by the manufacturer. Absorbance
wasmeasured immediately on spectrophotometer at 450 nmwith
dual wavelength, using 620 nm as reference wavelength.
Statistics
Positivity was identified using background-adjusted absorbance
of provided cut-off control. Background-adjusted sample
absorbance above the positive control are denoted as high-
positive. Comparison of qualitative variables between groups
was assessed using Fisher’s Exact Probability test with probability
(P) of <0.05 considered significant.
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RESULTS
Plasma anti-C. albicans antibody positivity was found in 36.5%
(19/52) of children with ASD. There was a significantly higher
percent positivity of plasma anti-C. albicans antibodies in
children with ASD than in healthy TD controls (14.3%; 4/28),
with an unadjusted odds ratio of 3.45 (95% confidence interval,
1.040 to 11.465; p = 0.041, two-tailed; Table 1). Nine of the 19
positive samples in children with ASD were considered high-
positive, versus only one high-positive in the TD population
(Figure 1). When examining ASD children with positivity
for anti-Candida IgG, 9 of 19 (47%) had symptoms of GI
dysfunction, of the 33 negative for anti-Candida IgG 13 had
GI symptoms (39%), however no significant differences were
observed based on presence or absence of GI symptoms in
children with ASD. In comparison, 1 of 4 TD children positive for
anti-Candida IgG had GI issues (25%) and only 5 of 24 who were
negative for anti-Candida IgG (21%), however, these data are
limited by small sample size of the TD group with GI symptoms.
DISCUSSION
Study of the microbiota-gut-brain axis has exploded over the
past few decades, however, fungal microbiota research is still
in the early stages. Fungal overgrowth has been implicated
TABLE 1 | The frequency of plasma anti-Candida albicans antibodies in children
with ASD compared to typically developed children.
Study group Anti-C albicans Anti-C albicans
IgG positive IgG negative
ASD 19 33
36.5% 63.4%
TD 4 24
14.3% 85.7%
P value 0.04
OR (95% CI) 3.45
OR, odds ratio.
FIGURE 1 | Candida albicans plasma positivity in ASD vs. typically developing
children. Nineteen children with ASD were positive for C. albicans IgG
antibodies compared to four typically developing children.
in inflammatory bowel disorders (39–41), schizophrenia and
bipolar disorder (36), and was recently discovered within the
cells of post-mortem brain tissue in Alzheimer’s patients (42).
Our results indicate that children with ASD have elevations
in IgG against this fungal commensal, likely indicating an
overgrowth ofCandida albicanswithin the GI tract. The source of
dysbiosis and Candida overgrowth in ASD is currently unknown
but may be influenced by the immune dysfunction seen in
many children with ASD. Alternatively, this overgrowth may be
contributing to immune and GI dysfunction and the behaviors
seen in ASD. This raises questions as to whether dysbiosis
is present very early in life in ASD and may be involved
in the etiology of ASD that need further investigation. IgG
antibodies to commensal organisms become more common as
individuals age, possibly due to transient intestinal breeches
that might occur during enteric infections or dysbiosis from
antibiotics, therefore identifying earliest exposure is a key next
step to this research. Future research should attempt to identify
presence of IgM antibodies which indicate current or very recent
infection (35), ideally during infancy and/or early life to see
if there is a relationship between infection and ASD symptom
emergence.
The presence of Candida species is known to alter the
assembly of microbiota after antibiotics, contributing to dysbiosis
in mice (25). This suggests that if present, a different
bacterial composition will occur than when absent. Therefore,
if Candida is present in very early life it could interfere
with initial colonization and the successions of composition
during the early transitional stages of microbiota development
leading to dysbiosis (43). The early microbiota are typically
inherited from maternal sources, especially during vaginal
delivery (43). If Candida is overgrown in mother during
gestation, it could potentially be passed on to offspring
as an early colonizer, interfering with normal colonization.
Furthermore, the immune response to fungal overgrowth
includes elevations of interleukin (IL)-17 (44). This cytokine
is implicated in maternal immune activation (MIA) models
of ASD, and without it ASD behaviors in MIA offspring
were absent (45, 46). Further research utilizing animal models
of fungal dysbiosis in early life or gestation could help
determine the degree in which fungal microbiota may be
contributing to the dysbiosis and behavioral abnormalities in
offspring.
To our knowledge, this is the first study to look at anti-
Candida albicans IgG in children with ASD. Our recent work
identified an imbalance in inflammatory versus regulatory
cytokines such as transforming growth factor (TGF) beta,
with alterations in the microbiota in this same population
based cohort (22). Although GI symptoms were not strongly
associated with Candida IgG positivity, we previously found
microbiota changes in individuals with ASD irrespective of GI
symptoms (22). This suggests that dysbiosis could occur even
in the absence of GI symptoms. This preliminary study was
initiated to guide future research on the fungal microbiota
and ASD. Further validation of our results could include
exploring fungal composition within the gut as well as metabolic
byproducts of yeast species such as d-arabinitol and ethanol,
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and identifying associations these might have with behaviors
in ASD.
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